A detailed history of Diversified Trust CO transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Diversified Trust CO holds 7,418 shares of BPMC stock, worth $830,519. This represents 0.02% of its overall portfolio holdings.

Number of Shares
7,418
Previous 15,676 52.68%
Holding current value
$830,519
Previous $1.45 Million 55.42%
% of portfolio
0.02%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 07, 2025

SELL
$82.48 - $101.39 $681,119 - $837,278
-8,258 Reduced 52.68%
7,418 $646,000
Q3 2024

Oct 07, 2024

SELL
$84.1 - $120.5 $19,679 - $28,197
-234 Reduced 1.47%
15,676 $1.45 Million
Q2 2024

Jul 16, 2024

BUY
$85.18 - $108.78 $122,488 - $156,425
1,438 Added 9.94%
15,910 $1.71 Million
Q1 2024

Apr 18, 2024

BUY
$73.17 - $99.79 $36,438 - $49,695
498 Added 3.56%
14,472 $1.37 Million
Q4 2023

Jan 08, 2024

BUY
$43.96 - $92.84 $121,109 - $255,774
2,755 Added 24.56%
13,974 $1.29 Million
Q3 2023

Nov 17, 2023

BUY
$46.9 - $66.0 $14,914 - $20,988
318 Added 2.92%
11,219 $563,000
Q2 2023

Jul 18, 2023

BUY
$42.2 - $66.37 $2,194 - $3,451
52 Added 0.48%
10,901 $688,000
Q1 2023

Apr 07, 2023

BUY
$37.97 - $50.0 $129,287 - $170,250
3,405 Added 45.74%
10,849 $488,000
Q4 2022

Jan 17, 2023

BUY
$41.06 - $66.48 $985 - $1,595
24 Added 0.32%
7,444 $326,000
Q3 2022

Oct 14, 2022

SELL
$49.93 - $77.7 $9,886 - $15,384
-198 Reduced 2.6%
7,420 $489,000
Q4 2021

Jan 13, 2022

BUY
$94.25 - $115.99 $293,588 - $361,308
3,115 Added 69.18%
7,618 $816,000
Q3 2021

Jan 13, 2022

BUY
$80.98 - $109.47 $364,652 - $492,943
4,503 New
4,503 $463,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $6.69B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Diversified Trust CO Portfolio

Follow Diversified Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Diversified Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Diversified Trust CO with notifications on news.